 |
市场调查报告书
商品编码
1427023
2024年医药产业5大成长机会Top 5 Growth Opportunities for the Pharmaceutical Industry, 2024 |
||||||
技术支援的合作伙伴关係加速了精准肿瘤学、罕见疾病和肥胖症领域的药物研发和开发
到 2024 年，生命科学 (LS) 产业预计将更加关注精准健康。 LS公司将提高基于体学的研究能力，部署人工智慧和生物资讯学，并越来越发现个人化治疗方法。製药公司和技术供应商之间的合作伙伴关係预计将继续扩大，以支持罕见疾病、肥胖和癌症的药物研发发现创新。
针对先前无法成药的目标的潜力正在药物研发核糖核酸 (RNA) 技术、蛋白质降解 (PROTAC) 和抗体工程技术的投资和合作。透过在关键重点领域建立更多的官民合作关係，精准肿瘤学正在加强。製药公司、委外研发机构(CRO)、数位疗法 (DTx)、诊断公司、真实世界证据 (RWE) 解决方案供应商、次世代定序(NGS) 公司和医疗设备製造商之间的跨产业合作。协作以增加。人工智慧的部署将得到加强，以加速药物研发和再利用、临床试验民主化和设计、RWD分析、製造自动化和供应链透明度，从而使患者、医疗保健提供者和製药行业受益，并惠及整个行业。
目录
2024 年主要成长机会
- 策略要务
- 5 大成长机会
- 成长机会1：利用人工智慧治疗罕见疾病药物的重复利用
- 成长机会 2：中东/亚太地区精准肿瘤学规模化的 PPP
- 成长机会3：药物研发发现与开发的敏捷合作模式
- 成长机会 4：利用新兴生物技术平台瞄准药物研发的蛋白质
- 成长机会5：肥胖治疗的联合治疗
- 下一步
- 免责声明
Tech-enabled Partnerships Propelling Drug Discovery and Development in Precision Oncology, Rare Diseases, and Obesity
In 2024, the life science (LS) industry's focus on precision health will intensify. LS companies will augment their omics-based research capabilities and increasingly deploy AI and bioinformatics to discover personalized therapies. Partnerships between pharmaceutical companies and technology vendors will multiply, to support innovation in drug discovery for rare diseases, obesity, and oncology.
The possibility of targeting previously undruggable targets will drive investments and partnerships in ribonucleic acid (RNA) technology, protein degradation (PROTAC), and antibody engineering technologies. Precision oncology is a vital area of focus, reinforced by the establishment of more public-private partnerships. There will be an increase in cross-industry collaboration between pharmaceutical companies, contract research organizations (CROs), digital therapeutics, diagnostic companies, real-world evidence (RWE) solution vendors, next-generation sequencing (NGS) companies, and medical device players. The implementation of artificial intelligence will intensify for accelerated drug discovery and drug repurposing, clinical trial democratization and design, RWD analysis, manufacturing automation, and supply chain transparency, with resulting benefits extending to patients, healthcare providers, and the pharmaceutical industry overall.
Table of Contents
Top Growth Opportunities for 2024
- Strategic Imperatives
- Top 5 Growth Opportunities
- Growth Opportunity 1: AI-enabled Drug Repurposing for Rare Diseases
- Growth Opportunity 2: PPPs for Precision Oncology Scaleup in Middle East and APAC
- Growth Opportunity 3: Agile Partnership Model for Drug Discovery and Development
- Growth Opportunity 4: Targeting Undruggable Proteins with Emerging Biotech Platforms
- Growth Opportunity 5: Combination Therapies for Obesity Management
- Next Steps
- Legal Disclaimer
